Corvus Pharmaceuticals, Inc. (CRVS) Stock Overview
Explore Corvus Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Corvus Pharmaceuticals, Inc. (CRVS)
Key Financials
Key Financials
Market Cap
1.1B
P/E Ratio
-23.90
EPS (TTM)
$-0.52
ROE
-0.39%
CRVS Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Corvus Pharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of CRVS on the NASDAQ shows an RSI of 40.37, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $18.32 for the NASDAQ listing.
Key metrics behind Corvus Pharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of -23.90 and a market capitalization of 1.1B. Combined with our AI analysis, these give both institutional and retail investors a clear view of CRVS on the NASDAQ.